Every 8-K that NeoGenomics, Inc. (NEO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEO filings page.
NeoGenomics, Inc. reported that Alicia Olivo, Executive Vice President, General Counsel & Business Development, will transition from her role and cease to serve as General Counsel effective September 21, 2026. She will remain an employee through October 2, 2026 for transitional purposes.
The company states that, in connection with her departure, Ms. Olivo will be eligible to receive separation payments and benefits in line with Section 5(b) of her employment agreement, which had been filed previously as part of NeoGenomics’ Form 10-K for the year ended December 31, 2025.
NeoGenomics, Inc. reported strong Q2 2026 growth with total revenue of $202 million, up 11% year over year. Clinical services revenue rose 14% to $187 million, supported by 26% NGS growth. Gross profit increased to $91.9 million with gross margin at 45.6% and adjusted gross margin at 48.1%. Operating expenses fell 19%, aided by the absence of prior-year impairment charges, narrowing the operating loss to $9.8 million.
GAAP net income was $2.2 million versus a $45.1 million loss a year earlier, including an $11.2 million gain on extinguishment of debt; adjusted net income reached $6.7 million and adjusted EBITDA grew 36% to $14.5 million. The company refinanced its convertible notes through a $316 million private offering of 0.75% notes due 2032, repurchased $276 million of 0.25% notes due 2028, entered capped call transactions to limit conversion dilution, and bought back $25 million of common stock, ending the quarter with $145.5 million of cash and equivalents. Updated 2026 guidance calls for revenue of $802–$806 million, net loss of $34–$42 million, and adjusted EBITDA of $56–$58 million.
NeoGenomics, Inc. filed an amendment to correct date references in a prior current report, changing erroneous “June 20, 2026” mentions in Items 7.01 and 8.01 to the correct date, July 20, 2026. The amendment restates those items but does not update any other prior disclosure.
The company had voluntarily conducted an internal investigation into the compliance of certain consulting and service agreements with federal healthcare laws and regulations and notified the Office of Inspector General of the U.S. Department of Health and Human Services in November 2021. On July 20, 2026, NeoGenomics finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving the government’s investigation concerning consulting services provided to certain health care providers. Under the settlement, NeoGenomics will pay $9,813,260. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities. The settlement agreement states it is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded.
NeoGenomics, Inc. reported that it finalized a civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving a government investigation into consulting services provided to certain health care providers under its Laboratory Collaboration Initiative program.
The company had voluntarily conducted an internal review of compliance with federal healthcare laws and self-disclosed the matter to OIG-HHS in November 2021. Under the settlement, NeoGenomics agreed to pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026. As of March 31, 2026, it had accrued a reserve of $11.2 million for potential damages and liabilities associated with this investigation. The settlement agreement states it is neither an admission of liability by NeoGenomics nor a concession by the United States regarding its claims.
NeoGenomics, Inc. filed a current report announcing that its Board of Directors increased in size from nine to ten members and appointed Carolyn S. Starrett as a new director, effective immediately. She will serve until the 2027 annual meeting of stockholders and then until a successor is elected and qualified.
Starrett brings more than 25 years of experience in data, technology, and oncology, including executive roles at Flatiron Health, where she served as CEO and Board Director, and prior board service at Foundation Medicine. NeoGenomics highlights her expertise in real-world data, AI, and analytics to support its oncology diagnostics and precision medicine strategy.
NeoGenomics, Inc. completed a private offering of $275.0 million of 0.75% Convertible Senior Notes due 2032, and an additional $41.25 million from the purchasers’ option, for total notes of $316.25 million in senior unsecured debt.
The notes carry 0.75% annual interest, payable semiannually, and mature on July 1, 2032, with conversion initially at 70.6140 shares per $1,000 (about $14.16 per share), a 35% premium to the $10.49 share price on June 16, 2026. NeoGenomics entered into capped call transactions with a $20.98 cap and paid about $28.7 million for them to help limit dilution on conversion.
The company relied on private offering exemptions and may issue up to 30,147,733 shares upon conversion, based on the initial maximum conversion rate. Concurrently, it repurchased approximately $276.0 million principal of 0.25% convertible notes due 2028 for about $263.19 million and arranged up to $25.0 million of share repurchases at $10.49 per share.
NeoGenomics, Inc. is privately offering $275 million of 0.75% convertible senior notes due 2032 to qualified institutional buyers, with an additional $41.25 million option for initial purchasers. The notes are convertible into cash, common stock, or a mix, at the company’s election.
The initial conversion rate is 70.6140 shares per $1,000, implying a conversion price of about $14.16 per share, a 35% premium to the $10.49 last sale price. NeoGenomics expects net proceeds of about $266.15 million, or $306.16 million if the option is fully exercised.
The company plans to spend about $25 million on capped call transactions with a $20.98 cap price, repurchase $276 million principal of 0.25% convertible notes due 2028 for about $263.19 million, and may repurchase up to $25 million of common stock, using any remaining proceeds for general corporate purposes.
NeoGenomics, Inc. plans a private offering of $275 million aggregate principal amount of convertible senior notes due 2032, limited to investors reasonably believed to be qualified institutional buyers. An option may allow initial purchasers to buy up to an additional $41.25 million of notes.
The notes will be senior unsecured obligations, maturing on July 1, 2032, with semi-annual interest and investor conversion rights. NeoGenomics may redeem the notes for cash after July 6, 2029 if its share price meets a 130% conversion-price threshold. The company plans capped call transactions and expects to use proceeds to help fund these, repurchase a portion of its 0.25% convertible notes due 2028, repurchase up to $25 million of common stock from certain note purchasers, and for general corporate purposes.
NeoGenomics, Inc. reported results of its annual stockholder meeting. Stockholders approved a second amendment to the 2023 Equity Incentive Plan, increasing the shares authorized for issuance under the plan by 5,000,000 shares.
A total of 116,630,120 shares were present or represented by proxy, representing approximately 89.61% of outstanding voting stock as of March 23, 2026, ensuring a strong quorum. All nine director nominees were elected. Stockholders gave majority advisory approval to compensation for the Named Executive Officers, approved the incentive plan amendment, and ratified the appointment of Deloitte & Touche LLP as independent registered public accountant.
NeoGenomics, Inc. reported strong first quarter 2026 results with revenue rising 11% year over year to a record $187 million, driven by 14% growth in Clinical revenue and higher average revenue per test.
Net loss narrowed 34% to $17.1 million, while Adjusted EBITDA improved to $9.0 million from $7.1 million, and Adjusted Net Income reached $1.4 million. Gross profit rose to $80.9 million with a 43% margin, and adjusted gross margin was 46%.
The company raised its full-year 2026 revenue guidance to $797–$803 million, implying about 10% growth from 2025, and reaffirmed Adjusted EBITDA guidance of $55–$57 million. NeoGenomics also launched its RaDaR ST MRD assay, expanded its PanTracer portfolio, and ended the quarter with $146 million in cash and cash equivalents.
NeoGenomics, Inc. reported fourth-quarter and full-year 2025 results showing solid revenue growth but continued net losses. Fourth-quarter revenue rose 11% to $190.2 million, with full-year revenue up 10% to $727.3 million, driven by higher test volumes and a shift toward higher value oncology diagnostics.
Fourth-quarter net loss improved to $9.9 million from $15.3 million, while full-year net loss widened to $108.0 million due to items such as impairment and litigation costs. Non-GAAP adjusted EBITDA was positive $13.4 million in Q4 and $43.4 million for 2025, both modestly higher than 2024.
The company highlighted strong growth in next‑generation sequencing, progress on its RaDaR ST minimal residual disease assay, and a successful resolution of RaDaR ST patent litigation. For 2026, NeoGenomics guides revenue to $793–801 million, a smaller GAAP net loss of $50–63 million, and adjusted EBITDA of $55–57 million.
NeoGenomics reported select preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025, while emphasizing that these figures are based on management estimates and may change after the year-end audit.
The company also outlined a planned finance leadership transition. Chief Financial Officer Jeffrey S. Sherman notified the board of his intention to retire and will move to Executive Vice President, Finance on March 2, 2026, serve in that role until April 14, 2026, and then act as a special advisor through April 2028. Abhishek Jain has been appointed Executive Vice President, Finance and is expected to become Chief Financial Officer on March 2, 2026. His compensation includes a $520,000 annual base salary, a target annual bonus equal to 60% of salary, and an initial equity award valued at $2,750,000 split evenly between three-year vesting restricted stock units and premium-priced stock options.
NeoGenomics, Inc. (NEO) announced that it furnished a press release reporting results for its third fiscal quarter of 2025. The press release, dated October 28, 2025, is included as Exhibit 99.1.
The company states this information is furnished and is not deemed “filed” under Section 18 of the Exchange Act, and it is incorporated by reference only if specifically referenced in other filings.
NeoGenomics disclosed that director Elizabeth Floegel resigned from the Company’s Board, effective immediately. The filing expressly states her resignation did not result from any disagreement with the Company on its operations, policies or practices. The notice is a straightforward governance update recorded under Item 5.02 and does not include any additional information about reasons beyond the statement or any immediate replacement for the Board seat.
This disclosure informs investors of a change in board composition while explicitly denying any dispute with management; the filing contains no financial data, operational changes or other material transactions.
NeoGenomics has announced a significant board expansion and appointment in a Form 8-K filing. The company's Board of Directors has increased its size from nine to ten members with the appointment of Marjorie C. Green as a new director, effective June 19, 2025.
Key details of the appointment include:
- Ms. Green will serve until the 2026 annual meeting of stockholders or until resignation/removal
- She will receive compensation aligned with the company's existing independent director compensation program as disclosed in the 2025 proxy statement
- The appointment was publicly announced via press release on June 24, 2025
The filing, signed by EVP and General Counsel Alicia C. Olivo, includes standard regulatory disclosures and confirms that NeoGenomics is not classified as an emerging growth company. The company trades on the Nasdaq Stock Market under the symbol NEO.